MTOR and breast carcinoma: Apart from that, PI3K was shown as target to sensitize breast cancer cells for adriamycin toxicity [49] and the combined PI3K/mTOR inhibitor BEZ235, that we also used here, was shown to sensitize genetically modified CDDP resistant breast cancer cells for cytotoxicity in a recent study [50].